Curtis A Thibeault, DMD in Alton, NH - Dentist

Curtis A Thibeault, DMD is a Dentist based in Alton, New Hampshire. Curtis A Thibeault is licensed to practice in New Hampshire (license number 04412) and his current practice location is 291 Main Street, Alton, New Hampshire. He can be reached at his office (for appointments etc.) via phone at (603) 855-2017.

NPI number for Curtis A Thibeault is 1205328085 and his current mailing address is 40 Winter St Ste 201, Rochester, New Hampshire. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1205328085.

Contact Information

	Curtis A Thibeault, DMD
	291 Main Street, Alton, NH 03809
	(603) 855-2017
	Not Available

Healthcare Provider's Profile

Full Name	Curtis A Thibeault
Gender	Male
Speciality	Dentist
Location	291 Main Street, Alton, New Hampshire
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1205328085
Provider Enumeration Date: 06/06/2018
Last Update Date: 09/02/2020

Medical Identifiers

Medical identifiers for Curtis A Thibeault such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1205328085	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
122300000X	Dentist	04412 (New Hampshire)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Curtis A Thibeault is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Curtis A Thibeault, DMD 40 Winter St Ste 201, Rochester, NH 03867-3139 Ph: (603) 332-7300	Curtis A Thibeault, DMD 291 Main Street, Alton, NH 03809 Ph: (603) 855-2017

News Archive

Investigational, orally-inhaled therapy effective in treating migraines

A new study conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania shows an investigational, orally-inhaled therapy is effective in treating migraines.

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Since its approval in 2011, the multiple sclerosis drug fingolimod (Gilenya) has already undergone three early benefit assessments, all of which were mainly based on the approval study TRANSFORMS. After a new modification of the therapeutic indication by the regulatory authorities, the Federal Joint Committee again commissioned the German Institute for Quality and Efficiency in Health Care to examine the added benefit of the drug in accordance with the Act on the Reform of the Market for Medicinal Products.

Washington Post examines Jamaican campaign to address HIV/AIDS stigma

The Washington Post on Sunday examined an HIV/AIDS campaign launched last year in Jamaica that aims to "destigmatize" the disease and to teach HIV-positive people the "importance of protecting others" from contracting the virus.

Insmed third quarter revenues decrease to $0.4 million

Insmed Incorporated, a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011.

Curtis A Thibeault, DMD - Dentist in Alton, NH